Hormonelle Empfängnisverhütung. Arbeitsgemeinschaft der Wissenschaftlichen
Medizinischen Fachgesellschaften e. V. (AWMF) e. V., abgerufen am 30. November 2021.
N. Sehovic, K. P. Smith: Risk of venous thromboembolism with drospirenone in combined oral contraceptive products. In: Ann Pharmacother., 44, 2010, S. 898–903. PMID 20371756.
J. Dinger, A. Assmann, S. Möhner, T. D. Minh: Risk of venous thromboembolism and the use of dienogest- and drospirenone-containing oral contraceptives: results from a German case-control study. In: J Fam Plann Reprod Health Care. 36, 2010, S. 123–129. PMID 20659364.
N. Idota, M. Kobayashi, D. Miyamori, Y. Kakiuchi, H. Ikegaya: Drospirenone detected in postmortem blood of a young woman with pulmonary thromboembolism: A case report and review of the literature. In: Leg Med (Tokyo). 17(2), Mar 2015, S. 109–115. PMID 25454533.
C. Moser, D. Zoderer, G. Luef, M. Rauchenzauner, L. Wildt, A. Griesmacher, C. Seger: Simultaneous online SPE-LC-MS/MS quantification of six widely used synthetic progestins in human plasma. In: Anal. Bioanal. Chem., 403(4), Mai 2012, S. 961–972. PMID 22160205.